Table 1.
Frequency range of genomic and proteomic aberrations among endometrioid and non-endometrioid endometrial cancers
| Tumor characteristic | Frequency (range)
|
References | |
|---|---|---|---|
| EECs (%) | NEECs (%) | ||
| Aneuploidy | 10–50 | 70–95 | 116,118–120 |
| MSI+ | 20–23 | 15 | 26–28,30 |
| AKT1 mutation | 2–3 | 13 | 53,199 |
| ARID1A mutation | 40 | 0 | 113 |
| BRAF mutation | 0–23 | 11 | 88,92 |
| CDKN2A mutation | 10–30 | 44* | 163–165 |
| CTNNB1 mutation | 2–45 | 0** | 52,103,110 |
| FBXW7 mutation | 2–16 | 0 | 154,155 |
| FGFR2 mutation | 5–16 | 2–3 | 100,101 |
| KRAS mutation | 8–43 | 2 | 57,80,88 |
| PIK3CA mutation | 20–52 | 33 | 57,62 |
| PIK3R1 mutation | 21–43 | 12 | 52,58 |
| PPP2R1A mutation | 3–7 | 17–41 | 133–135 |
| PTEN mutation | 26–79 | 13–19 | 57,198 |
| TP53 mutation | 5–20 | 53–90 | 60,122,125,129 |
| CCNE1 amplification | 5 | 42 | 154 |
| ERBB2 amplification | 1–63 | 17–42 | 137,138,200 |
| E-Cadherin negative expression | 5–53 | 62–88 | 173,174,176 |
| Claudin-3 positive expression | 38 | 74 | 167 |
| Claudin-4 positive expression | 9 | 63 | 167 |
| p16 positive expression | 5–38 | 63–100 | 160,161 |
Notes:
*
Based on an analysis of twelve tumors;
**
based on an analysis of nine tumors.